CXCL12 and Miyoshi myopathy: In more detail, acquisition of BRAF or other activating RAS pathway mutations reduced expression of adhesion molecules or chemokines, altered SDF1/CXCR4 axis interaction, and enhanced angiogenesis as drivers of MM disseminations (Figure 2) [80,88,89,90,91,92]; the MM niche represents an environment where the tumor is able to proliferate, taking advantage of a protective milieu composed by activated stromal and endothelial cells, capable of promoting invasion and angiogenesis.